Immunity to Pathogens Taught by Specialized Human Dendritic Cell SubsetsSelf-Amplifying Replicon RNA Vaccine Delivery to Dendritic Cells by Synthetic NanoparticlesAn mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn PigsRabies Control and Treatment: From Prophylaxis to Strategies with Curative PotentialRapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice.Strategies for cancer vaccine development.Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula.Characterization of the ribonuclease activity on the skin surface.Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients.Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion.Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa studyEnhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in SituLong-term storage of DNA-free RNA for use in vaccine studiesHLA class I transgenic mice: development, utilisation and improvement.Nonviral delivery of self-amplifying RNA vaccines.Some considerations on the use of peptides and mRNA for therapeutic vaccination against cancer.Developing mRNA-vaccine technologies.Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals.Medical treatment of pancreatic cancer.Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines.Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy.Melanoma vaccines: developments over the past 10 years.mRNA vaccination as a safe approach for specific protection from type I allergy.mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic.Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines.A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugsmRNA-based dendritic cell vaccines.The ReNAissanCe of mRNA-based cancer therapy.Self-replicating alphavirus RNA vaccines.mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer.CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes.Viral and Synthetic RNA Vector Technologies and Applications.Introduction to RNA Vaccines.In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles.The European Regulatory Environment of RNA-Based Vaccines.Aging, cancer, and cancer vaccinesSelective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation.mRNA vaccines - a new era in vaccinology.The messenger's great message for vaccination.
P2860
Q26777195-CA45CEB2-F2A5-462D-97C6-697663F2D9F9Q27027078-9DA8AD05-B3BB-49E4-ADA4-E0AE72FF50DDQ27303650-8522514A-3DC6-43F2-A76E-36CC75326F3BQ28076429-D32D4323-5D83-4E85-A551-26CA2B005FF9Q30375250-C7BB0396-7539-428F-B999-291D2D7AD48EQ34038338-4ED40A0F-C546-4F87-9570-D0E2CD1F6D17Q34422110-65E59643-1F27-46BD-A6F1-D56713FE3801Q34880734-26750C45-D91B-4DA7-9217-F6198DB56516Q34994511-9664BE23-DC0C-4949-B565-1B68D8B8EA69Q35558828-DDD3D511-F017-4E94-B95F-B1A4D5430C5BQ35746834-24417F77-A2D7-43F6-8B06-4334595A7F6EQ35826688-6ECEA9F2-A8A5-4683-80EA-74895A50AB71Q35920469-B2594854-44D1-4712-9318-D430E29E3469Q36194073-DDCA4341-E4D4-4C12-9856-FD8BE8173338Q36221799-69C71D11-8256-470B-B3F1-7E1223DA868FQ36471822-6A27137F-0836-4BF2-BD29-B8F88C62BFA2Q36684597-70EA63DE-F47D-45FB-97F1-F0697E751D80Q36757051-558B5751-A628-4189-BEEF-B47ED18B2146Q36788494-600F2DBA-2392-41A5-86D6-DD1E1A304787Q37416925-7C903D85-A743-4D06-88B1-B4F87FB72DAEQ37530550-E7FE42AC-33ED-42EE-A524-6A480D058FC4Q37559326-DAED9C8A-EEB7-419E-9871-28F2440E5492Q37892595-9079FD33-4C35-4C83-A5B6-727FC91DAFA7Q37965722-F5550AFC-5878-446D-BC0D-6F768D15222FQ38071900-0C137313-DEB3-458E-B05C-69715947A78FQ38199151-D066FA6C-CFC9-4E4B-B292-80FD76BF223EQ38206520-5D9140AE-075A-4D04-BB18-4041E628D94BQ38246769-EF53CFB5-2054-46B9-9521-52EAE77BF6DEQ38255012-BF511785-C04D-4789-99F4-ECEF226F5A63Q38255634-78E7F5D4-257E-432A-9D83-3989E6720FB9Q38284699-3D6B4662-7159-4258-9CC2-B675B0A0D9CDQ38853141-448C081B-0F05-4009-9749-C1EF4E2C3AA0Q38885624-94AFAD57-301D-4B26-95E2-005AD26BBCACQ39041939-99AC9872-22B0-47C8-B83C-F8C8C80F86A5Q39574217-538A7D01-E47E-45B3-A4AD-114138BAFE18Q40405913-A719F100-B750-4688-A4B1-C808A8919F17Q42172986-0E693FED-B717-4CE9-B4F5-7D618B5DE4E8Q45867833-B9FD7A3A-7D41-423B-9E98-A6C27E2B5F6DQ47736893-8195242E-6BB5-4E93-BA16-36895C14F68CQ51068251-379F3DFB-05FF-4FA7-B6D1-4700F5EA39AF
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Messenger RNA-based vaccines.
@ast
Messenger RNA-based vaccines.
@en
type
label
Messenger RNA-based vaccines.
@ast
Messenger RNA-based vaccines.
@en
prefLabel
Messenger RNA-based vaccines.
@ast
Messenger RNA-based vaccines.
@en
P2860
P1476
Messenger RNA-based vaccines.
@en
P2093
Steve Pascolo
P2860
P304
P356
10.1517/14712598.4.8.1285
P407
P577
2004-08-01T00:00:00Z